Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

gated hyperbilirubinemia.  Average alanine aminotransferase (ALT) improved in all BI 201335 groups compared to placebo, and there was no excess anemia reported in the study.  Across BI 201335 treatment groups, 4 to 12 percent of patients discontinued BI 201335 due to AEs.  

(Oral abstract #66) SILEN-C2: Sustained Virologic Response and Safety of BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Patients with Non-Response to PegIFN/RBVThe SILEN-C2 study evaluated the virological response and safety of different doses of BI 201335 in treatment-experienced patients who did not respond to at least 12 weeks of prior treatment with PegIFN/RBV. This patient population is particularly difficult to treat, as patients who have not responded to PegIFN/RBV alone have low response rates to additional treatments. The trial did not include patients who relapsed after initial treatment with PegIFN/RBV.

In this double-blind, randomized, placebo-controlled trial, 288 treatment-experienced GT-1 HCV patients were randomized (2:1:1) to receive either:

  • BI 201335 240mg QD with a three-day LI of PegIFN/RBV;
  • BI 201335 240mg QD plus PegIFN/RBV without LI; or
  • BI 201335 240mg twice-daily (BID) with a three-day LI of PegIFN/RBV

  • In each group, patients were given BI 201335 for 24 weeks in combination with PegIFN/RBV, which was given for 24 or 48 weeks.

    Patients in the two BI 201335 QD groups who achieved eRVR were re-randomized to either stop all treatment at Week 24 or continue PegIFN/RBV until Week 48.

    Treatment Outcomes in SILEN-C2 (Treatment-Experienced Patients)240mg
    QD/LI
    (N=142)240mg
    QD
    (N=76)240mg
    BID/LI
    (N=70)eRVR, %

    43

    45

    47Overall SVR, %

    28

    41

    31Breakthrough*, %

    25

    28

    17Relapse**, %

    25

    9

    19*Rebound on treatment with BI 20133
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
    7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
    10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
    11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
    (Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
    (Date:7/10/2014)... , July 10, 2014 Integrated Silicon Solution, ... advanced memory and analog IC solutions, today announced that ... July 24, 2014, at 7:00 a.m. Pacific Time (10:00 ... for the fiscal 2014 third quarter ended June 30, ... telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time on ...
    Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
    ... SAN DIEGO, March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... City.   The live presentation takes place ... / 10:20 a.m. Pacific Time.  The presentation will be webcast ...
    ... AAIPharma Services Corp., a leading provider of ... its compendial raw materials testing group to a ... Wilmington, N.C., headquarters facility. The move follows a ... analytical testing business. (Logo:   http://photos.prnewswire.com/prnh/20110330/CG74146LOGO ...
    Cached Medicine Technology:AAIPharma Services Announces Compendial Testing Facility Expansion 2
    (Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
    (Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
    (Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
    (Date:7/13/2014)... 2014 Fadhits.com is popular among worldwide ... are extremely beautiful. Recently, the company has announced its ... 2014. What’s more, all these outfits are available at ... , Additionally, the supplier is now offering similar discounts ... dresses, it has many other designs for sale, including ...
    (Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
    Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
    ... New findings show that treatment with a specific alpha ... for men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). ... relaxing the muscles in the bladder neck and prostate. ... States, the EU and Japan to treat painful symptoms ...
    ... 11 (HealthDay News) -- Some men with enlarged prostate ... severe complications as a result, according to a new ... for enlarged prostate, the rate of men operated on ... the rate of discharges for men for enlarged prostate ...
    ... NJIT and UMDNJ have executed a license agreement with The ... on which a patent is pending. The tonometer ... Gordon Thomas, PhD, and Robert Fechtner, MD, director of the ... was a member of the research team. "We ...
    ... address a major new risk for the global supply ... the supply chain as pharmaceutical companies increasingly outsource the ... topic of the cover story in the current edition ... C&EN Senior Editor Rick Mullin explains that ...
    ... first time, researchers at McMaster University have conclusive evidence ... and behaviour. The findings are important because several ... are frequently associated with anxiety or depression. In addition ... as late onset autism, may be associated with an ...
    ... new study led by the University of Leicester has concluded ... in a doctor,s surgery helps to reduce emergency hospital admissions. ... Sciences at the University of Leicester revealed a correlation between ... hospital admissions. The research, published in Emergency Medical ...
    Cached Medicine News:Health News:Experimental treatment offers relief from painful prostate condition 2Health News:Fewer Men Having Surgery to Treat Enlarged Prostate: Study 2Health News:NJIT and UMDNJ license personal tonometer technology for innovative glaucoma testing 2Health News:That anxiety may be in your gut, not in your head 2Health News:Patients who see preferred doctor less likely to go for emergency hospital admission 2
    For the qualitative and semi-quantitative measurement of RF in human serum....
    ... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
    Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
    ... For use as a quality ... IgG antibody to Toxoplasma gondii ... rubella virus (rubella IgG), IgG ... and IgG antibody to herpes ...
    Medicine Products: